Woodline Partners LP Eledon Pharmaceuticals, Inc. Transaction History

Woodline Partners LP

$14.3 Billion
Q1 2025

A detailed history of Woodline Partners LP transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,671,822 shares of ELDN stock, worth $5.72 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,671,822

Previous 1,671,822 -0.0%

Holding current value

$5.72 Million

Previous $6.84 Million 17.11%

% of portfolio

0.04%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.45 - $5.3 $2.03 Million - $4.39 Million	828,930 Added 98.34%	1,671,822 $6.84 Million
Q3 2024 Nov 14, 2024	BUY	$2.41 - $3.19 $404,034 - $534,800	167,649 Added 24.83%	842,892 $2.1 Million
Q2 2024 Aug 14, 2024	BUY	$1.57 - $3.12 $36,587 - $72,708	23,304 Added 3.57%	675,243 $1.78 Million
Q1 2024 May 15, 2024	SELL	$1.54 - $2.13 $57,597 - $79,664	-37,401 Reduced 5.43%	651,939 $1.34 Million
Q4 2023 Feb 14, 2024	BUY	$1.12 - $1.86 $95,588 - $158,745	85,347 Added 14.13%	689,340 $1.24 Million
Q3 2023 Nov 14, 2023	BUY	$1.14 - $1.66 $99,542 - $144,947	87,318 Added 16.9%	603,993 $827,000
Q2 2022 Aug 15, 2022	SELL	$2.34 - $3.96 $366,123 - $619,593	-156,463 Reduced 23.24%	516,675 $1.26 Million
Q1 2022 May 16, 2022	SELL	$3.06 - $4.89 $331,208 - $529,283	-108,238 Reduced 13.85%	673,138 $2.65 Million
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.46 $451,849 - $643,543	-76,069 Reduced 8.87%	781,376 $4.83 Million
Q2 2021 Aug 16, 2021	SELL	$7.62 - $11.75 $256,108 - $394,917	-33,610 Reduced 3.77%	857,445 $6.78 Million
Q1 2021 May 17, 2021	BUY	$9.85 - $19.22 $8.78 Million - $17.1 Million	891,055 New	891,055 $9.53 Million

About Eledon Pharmaceuticals, Inc.

Ticker ELDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,756,800
Market Cap $47M
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...

More about ELDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Eledon Pharmaceuticals, Inc. Transaction History